SRPT
Sarepta Therapeutics, Inc.Company with tickers: SRPT
Market Cap
$1.76B
Shares Outstanding
105,576,222
CIK
873303
CUSIP
803607100
13F Activity (30d)
30 filings
6 filers
Website
Visit website
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Deirdre Connelly | director (Class I) | Appointed | 2026-06-04 |
| Michael Chambers | director (Class I) | Appointed | 2026-06-04 |
| Kathryn J. Boor, Ph.D. | director (Class I) | Appointed | 2026-06-04 |
| Hans Wigzell, M.D., Ph.D. | director (Class I) | Appointed | 2026-06-04 |
| Douglas S. Ingram | director (Class I) | Appointed | 2026-06-04 |